Neocytogen Theraputics
Biotechnology Research • 
1 Venture Avenue, Singapore, Singapore • 1-10 Employees
Company overview
| Headquarters | 1 Venture Avenue, Singapore, #01-08, Perennial Business City, Singapore, Singapore 608521, SG |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Research, Medicine, Ipsc, Oncolytic Virus, Exosome Technology, Car-X |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at Neocytogen Theraputics
Alan Xiao
Chief Technology Officer
About Neocytogen Theraputics
Neocytogen Therapeutics is a biotechnology company focusing on universal cell and gene therapy, committed to developing innovative therapies for malignant tumors and chronic diseases. The company's core technologies include universal CAR-X platform, iPSC platform, next generation oncolytic virus platform, and exosome technology platform. The founding team of Neocytogen is composed of senior scientists from the National University of Singapore and Nanyang Technological University. The company is headquartered in Singapore, with R&D centers in Singapore and Shanghai, China. We are also building an integrated center of R&D and production in Singapore to support future technology translation and clinical applications, enabling us to become a global leader in universal cell therapy. For more information, please refer to our website.
Neocytogen Theraputics revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Neocytogen Theraputics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Neocytogen Theraputics has never raised funding before.
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
